ArticleMolecular cancer therapeutics2022

Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.

Ping Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.